GlycoMimetics Inc (NASDAQ:GLYC) major shareholder Bvf Partners L. P/Il acquired 1,668,746 shares of the company’s stock in a transaction dated Thursday, September 5th. The shares were bought at an average cost of $3.18 per share, with a total value of $5,306,612.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.
Shares of GLYC opened at $4.60 on Thursday. GlycoMimetics Inc has a fifty-two week low of $2.64 and a fifty-two week high of $15.03. The firm has a market cap of $158.95 million, a price-to-earnings ratio of -3.90 and a beta of 2.71. The firm has a 50 day moving average price of $4.73 and a 200-day moving average price of $10.20. The company has a debt-to-equity ratio of 0.02, a quick ratio of 17.54 and a current ratio of 17.54.
GlycoMimetics (NASDAQ:GLYC) last released its earnings results on Thursday, August 1st. The biotechnology company reported ($0.37) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.01). As a group, equities research analysts predict that GlycoMimetics Inc will post -1.51 earnings per share for the current year.
A number of institutional investors have recently bought and sold shares of the business. Aperio Group LLC purchased a new stake in GlycoMimetics during the second quarter valued at about $49,000. BNP Paribas Arbitrage SA purchased a new position in shares of GlycoMimetics in the first quarter worth about $88,000. State Board of Administration of Florida Retirement System purchased a new position in shares of GlycoMimetics in the second quarter worth about $123,000. GSA Capital Partners LLP purchased a new position in shares of GlycoMimetics in the second quarter worth about $185,000. Finally, DekaBank Deutsche Girozentrale lifted its stake in shares of GlycoMimetics by 22.9% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 13,400 shares of the biotechnology company’s stock valued at $200,000 after acquiring an additional 2,500 shares during the last quarter.
GlycoMimetics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and is in a Phase III clinical trial, conducted by its strategic collaboration with Pfizer Inc It is also developing uproleselan, an E-selectin antagonist that is evaluated in a Phase I/II clinical trial as a potential treatment for acute myeloid leukemia (AML), as well as Phase III trial to treat relapsed/refractory AML.
Read More: Relative Strength Index
Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.